Trial
NCT00881387
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Miami
Collaborators
—
Condition
Lymphoma
Intervention
rituximab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-15